Search Results for 'aqueous humor'
-
Glaukos Completes Patient Enrollment in U.S. IDE Trial for iStent infinite
Trial is designed to evaluate the safety and performance of the company's Three-Stent System in a standalone procedure for advanced glaucoma.Business Wire 11.21.19
-
Data Show Glaukos’ iStent inject Delivers Greater IOP Reduction vs. iStent
iStent inject achieved greater absolute IOP declines with 93 percent of subjects medication-free vs. 76 percent of iStent subjects.Business Wire 11.20.19
-
Study Confirms Significant Medication Reduction After Implantation of Glaukos iStent inject
iStent inject achieved 42 percent reduction in Mean IOP to 14.6 mmHg and 82 percent reduction in mean medications to 0.55 at three years postoperative.Business Wire 07.23.19
-
Glaucoma Study Confirms Long-term Efficacy, Safety of Glaukos iStent Implantation
At five years postoperative, mean IOP decreased 38 percent to 14.7 mmHg and topical ocular hypotensive medication use fell 75 percent.Business Wire 04.24.19
-
Diagnostics
Color-Changing Sensor Detects Signs of Eye Damage in Tears
Gel laden with gold nanoparticles changes color when it reacts with a teardrop containing ascorbic acid.Liz Ahlberg Touchstone, University of Illinois at Urbana-Champaign 09.04.18
-
Electronics | Patient Monitoring
A Sentinel to Watch Over Ocular Pressure
EYEMATE is a microsensor system that enables patients to take contactless pressure measurements of their eyes.Fraunhofer-Gesellschaft 08.02.18
-
Surgical
FDA Approves Glaukos' iStent inject Trabecular Micro-Bypass System
Offers ophthalmic surgeons a compelling new treatment pption for managing glaucoma patients’ IOP.Business Wire 06.25.18
-
Study Shows Long-Term Titrated IOP Control With Glaukos iStent Trabecular Micro-Bypass Stents
Data reveal 30 percent to 43 percent reductions in unmedicated mean IOP for single or multiple iStent implantations.Business Wire 03.23.18
-
Study: Glaukos iStent Trabecular Micro-Bypass Stent Reduces IOP, Lowers Medication Burden
Combined with cataract surgery, iStent achieved a 28 percent reduction in mean medication use.Business Wire 03.01.18
-
Glaukos Submits IDE Application to FDA to Study iStent infinite Trabecular Micro-Bypass System
Three-stent device is designed to reduce IOP in refractory glaucoma patients.Business Wire 01.29.18
-
Glaukos to Begin Randomized U.S. IDE Pivotal Clinical Trial for the iStent SA System
Trial will enroll Pseudophakic Glaucoma subjects to assess the device’s safety, efficacy for reducing elevated IOP.Business Wire 01.22.18
-
Glaukos Issued New U.S. Patent
Latest patent covers ocular devices and methods of surgically implanting them.Business Wire 01.03.18
